- Eli Lilly issues data sharing ultimatum to 340B hospitals<figure><div><img src="https://imgproxy.divecdn.com/8nTrHlsFTcngJswJxr_8afos9dxh_YxQE6LZmgMA2_I/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzX2VHa…BioPharma Dive · 1mo ago↗ source
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug<figure><div><img src="https://imgproxy.divecdn.com/NkRGM2WlVG_bih055HG7zy8PbwZNjna8pIs5Yzt_9MI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTcwOTEzMjEwLmpwZ…BioPharma Dive · 1mo ago↗ source
- What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitCHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...